Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

A2 Milk says lift in dairy prices may impact in FY2020

By Rebecca Howard

April 3 (BusinessDesk) - A2 Milk Company said recent increases in dairy pricing will have an impact on gross margin percentages in the 2020 financial year but it doesn't anticipate any significant impact this year.

Dairy product prices rose for the ninth straight time in the overnight Global Dairy Trade auction. The GDT price index added 0.8 percent from the previous auction two weeks ago and average prices are now up 28 percent since the auction on Nov 20.

"We do not anticipate any significant impact to gross margin percentage during FY19 as a result of recent increases in dairy pricing as reflected in Global Dairy Trade Indices. However, these increases are likely to have some impact in FY20," A2 said in a presentation for investors in Sydney published on the stock exchange. Its financial year runs to June 30. Gross margin in the first half of the current financial year was 55.6 percent.

A2 Milk reiterated that it expects the group revenue growth rate in the second half to continue broadly in line with the first but second-half earnings before interest, tax, depreciation and amortisation margins will be lower. Full-year ebitda as a percentage of sales will be 31 to 32 percent due to marketing investment, investment in organisational capability and the weaker Australian dollar versus the kiwi dollar.

Revenue lifted 41 percent on the year in the first half to $613.1 million while ebitda was up 53 percent at $218.4 million.

Regarding the third quarter, A2 said its marketing programme is on track in China and it continues to strengthen its infant formula market share position. In Australia and New Zealand, it reiterated that it has not experienced any impact to infant formula sales from new e-commerce or cross border e-commerce regulations in China. In the US it cited "continuing positive momentum" in sales velocities and distribution growth for liquid milk.

First NZ Capital search analyst Tristan Joll said A2 has done "an excellent job of creating and managing demand for its A1 protein-free dairy products. The outcome is a business which has passed-through $1 billion in revenue with free cash flow that can support growth, upstream investment and potential capital returns. In our view, the outlook for the balance of full-year 2019 continues this momentum on."

He rates the stock at neutral but lifted his 12-month target price to $14 in a note published Wednesday. The stock last traded $14.58 and is up 31 percent so far this year.

Given the stock is trading at 12 percent above FNZC's revised spot discounted cash flow or DCF and on 30 times forward earnings per share "we view the stock as a more balanced investment proposition," said Joll.

(BusinessDesk)

ends

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Marine And Freshwater Reports: EDS Calls For Urgent Action On Marine Management

“There are some big issues to address. These include many marine species and habitats that are in serious trouble. Of the sample investigated, the report finds that 22% of marine mammals, 90% of seabirds and 80% of shorebirds are threatened with or actually at risk of extinction..." More>>

ALSO:

$7.5 Billion Surplus: Government Accounts "Show Strong Economy"

“The surplus and low levels of debt show the economy is in good shape. This allows the Government to spend more on infrastructure and make record investments in health and education,” Grant Robertson says. More>>

ALSO:

New OIO Application Trumps Judicial Review: OceanaGold Cleared To Buy Land For Waihi Tailings Expansion

In a surprise turnaround, the government has given OceanaGold a greenlight to buy land to expand its Waihi mine after the application was previously turned down by Land Information Minister Eugenie Sage. More>>

ALSO:

Christchurch Rebuild: Fletcher Sued For $7.5m Over Justice Precinct

Fletcher Building is being sued for $7.5 million by utilities contractor Electrix, one of the subcontractors on the Christchurch Justice and Emergency Services Precinct. More>>

Three New Drugs: PHARMAC Signs Bundle Deal For More Cancer Medicines

420 New Zealanders with lung cancer, breast cancer, multiple sclerosis and respiratory disease will benefit each year from a bundle deal PHARMAC has finalised with a medicine supplier. More>>

ALSO: